Renishaw plc
13 February
2025
Interim report
for the six months ended 31 December 2024 (H1
FY2025)
Steady progress in H1 with demand picking up at the start of
H2
|
6 months to
31 December
2024
|
6 months
to
31
December
2023
|
Change (%)
|
Revenue (£m)
|
341.4
|
330.5
|
+3
|
|
|
|
|
Profit before tax* (£m)
|
57.5
|
56.5
|
+2
|
|
|
|
|
Operating profit* (£m)
|
51.6
|
47.2
|
+9
|
|
|
|
|
Earnings per share*
(pence)
|
63.2
|
62.1
|
+2
|
|
|
|
|
Dividend per share
(pence)
|
16.8
|
16.8
|
-
|
|
|
|
|
Adjusted* cash flow from operating
activities (£m)
|
51.5
|
22.9
|
+125
|
|
|
|
|
Performance highlights
1. H1 FY2025 revenue 3% higher
at £341.4m (H1 FY2024: £330.5m):
· 2% revenue growth at constant exchange rates*, excluding
impact of forward contracts;
· Growth in Americas and EMEA, lower revenue in APAC;
· Manufacturing technologies up 4% at £322.6m, with
growth from Position Measurement and Additive
Manufacturing products, weaker demand from machine builders for
Industrial Metrology products; and
· Analytical instruments and medical devices 3% lower at £18.8m,
with growth in Neurological products offset by lower Spectroscopy
sales.
2. Profit before tax 2% higher
at £57.5m (H1 FY2024: £56.5m):
· Gross margin excluding engineering costs improved by 1.0% to
61.5%;
· Operating profit up 9% at £51.6m at actual exchange rates,
down 5% at constant currency; and
· Profit before tax in Q2 was lower than Q1 due to less
favourable currency contracts, adverse product mix, and one-off
supply chain costs.
3. Adjusted* cash flow
conversion from operating activities above target at 100%,
reflecting strong operating cash flows and planned lower capital
expenditure:
· Strong balance sheet, with cash and cash equivalents and bank
deposit balances of £233.2m (30 June 2024: £217.8m).
4. Continued progress on our
strategic priorities, with new product launches in H1 that
strengthen our position in established and emerging
markets.
5. Interim dividend of 16.8
pence per share.
6. Outlook:
·
Order intake recently improved, steady revenue
growth expected to continue in H2;
·
FY2025 revenue range:
£695m to
£735m; and
·
FY2025 adjusted profit before tax: £105m to
£135m.
* For
this period and the comparable period there is no difference between 'Statutory' and 'Adjusted' for some of
our alternative performance measures, being Adjusted profit before
tax, Adjusted earnings per share and Adjusted operating profit.
Note 12, Alternative performance measures,
defines how other alternative measures are calculated.
Will Lee, Chief Executive,
commented:
"We have continued to make steady progress in mixed trading
conditions and our order intake has recently improved, particularly
from the semiconductor manufacturing and consumer electronics
sectors. Supported by our strategic progress, we expect to achieve
steady revenue growth this year. Our markets present significant
structural growth opportunities, and we are confident that the
investment that we are currently making in productivity
improvements will drive our operating margins towards our 20%
target in the medium term."
About Renishaw
We are a world leading supplier of
measuring and manufacturing systems. Our products give high
accuracy and precision, gathering data to provide customers and end
users with traceability and confidence in what they are making.
This technology also helps our customers to innovate their products
and processes. We are a global business, with customer-facing
locations across our three sales regions; the Americas, EMEA, and
APAC. Most of our R&D work takes place in the UK, with our
largest manufacturing sites located in the UK, Ireland and
India.
Further information can be found
at www.renishaw.com
Results presentation
See below a video presentation of
these results, presented by Will Lee, Chief Executive, and Allen
Roberts, Group Finance Director.
Your
browser does not support HTML5
video.
Live Q&A session
There will be a live audio-only
question and answer session with Will and Allen at 10:30 GMT on 13
February 2025. Details of how to register for this webcast are
available at the following link:
https://www.renishaw.com/en/register-for-the-2025-interim-results-webcast--49582
Questions can be submitted in
advance of the webcast to communications@renishaw.com
(please submit by 9:30 GMT on 13
February).
A recording of the Q&A session will be made available by 14
February 2025 at: www.renishaw.com/investors.
Enquiries: communications@renishaw.com
Overview for the six months ended 31 December
2024
Revenue
Revenue for the six months ended 31
December 2024 was £341.4m, 3% higher than £330.5m for the
corresponding period last year. Manufacturing technologies revenue
increased by 4%, with growth in Position Measurement (PM) and
Additive Manufacturing (AM) products and weaker demand from machine
builders for Industrial Metrology (IM) products. Analytical
instruments and medical devices revenue was 3% lower, with growth
in Neurological products being offset by lower demand for
Spectroscopy products.
At constant currency*, Group revenue
increased by 2%. APAC revenue was down 1% at constant currency,
with weaker sales of IM products to the consumer electronics
sector, although orders from these customers have recently
improved. By contrast, sales of position encoders to
semiconductor equipment manufacturers rose during the period, also
supported by a strengthening order book. EMEA revenue was 5%
higher at constant currency, with strong growth in co-ordinate
measuring machine (CMM) systems, AM systems and position encoders,
but weaker demand for IM sensors from machine builders. Americas
revenue also grew by 5% at constant currency, with growth in AM
systems and position encoders, and also has an improved order
book.
|
6 months to
31 December
2024
|
6 months
to
31
December
2023
|
Change
%
|
Constant
fx* change %
|
Group revenue
|
£341.4m
|
£330.5m
|
+3%
|
+2%
|
Comprising:
|
|
|
|
|
APAC
|
£161.4m
|
£161.2m
|
+0%
|
-1%
|
EMEA
|
£102.3m
|
£97.2m
|
+5%
|
+5%
|
Americas
|
£77.7m
|
£72.1m
|
+8%
|
+5%
|
New
product introductions and commercialisation
We have made progress during the
first six months of the financial year in each of our three
strategic priorities:
1. Growing in our existing
markets - aiming to increase revenue
by driving up probe fitment levels, offering usable and higher
value sensors, and by winning more machine builder
customers.
· Enhanced the usability of our twin
probe system for machine tools, introducing patented Opti-Logicâ„¢
technology for fast set-up using a smartphone app.
· Launched enhancements to our range of modular metrology
fixtures, improving ease-of-use and reducing environmental
impact.
· Continued to win new customers and grow revenue from our
FORTiSâ„¢ enclosed position encoders, now featuring longer axis
lengths for larger machine tools.
2. Increasing the value of the
technology we sell - aiming to
provide our end-user customers with complete solutions to capture a
greater proportion of their investment.
· Launched the RenAM 500D dual laser AM machine, featuring our
patented TEMPUSâ„¢ technology, offering production speeds up to three
times faster than conventional single laser systems.
· Added five new processable materials for our AM machines and
new powder layer thicknesses for existing materials.
3. Extending into new,
high-growth markets - aiming to
diversify into close-adjacent markets where we have strong market
understanding and brand awareness.
· Launched our new ASTRiA™ inductive encoder line, offering
robust and accurate position measurement in demanding environments,
including robotics, defence and medical devices.
Operating
profit and costs
Operating profit for the period was
£51.6m, a 9.3% increase on the previous period. This amounts to 15%
of revenue, against 14% last year, and against our target of 20%.
The current period includes significant gains from forward currency
contracts, which were entered into at favourable rates following
volatility in currency markets arising from the September 2022 UK
'mini Budget'. These benefits were mostly experienced in Q1. When
excluding these, and translating H1 FY2025 results at FY2024
exchange rates, operating profit at constant exchange rates* was
4.9% lower than the previous year.
Labour costs have increased by £9.6m
compared to the prior financial year. This increase primarily
results from January 2024 salary reviews, plus a net headcount
increase of 98 (which mostly relates to graduates and apprentices).
Our salary review in January 2025 amounted to around 4% of our
total labour costs, which will increase our labour costs in the
second half of the financial year by around £7m. While we will
continue to invest in employee remuneration to ensure
competitiveness and retention of highly skilled and trained
employees, our recruitment plans will also need to consider the
impact of the UK Government's October 2024 Budget, which is
expected to increase FY2025 labour costs by £1m and will add £4m to
our annual costs.
Our gross margin (excluding
engineering costs) for the period was 61.5% of revenue, an
improvement of 1% over the comparable period in the previous year.
Within this gross margin, we have seen favourable variances
relating to currency and component purchase costs, however these
have been partly offset by continued pricing pressures,
particularly in the APAC region. We have also experienced a
specific supply chain quality issue during Q2, which has resulted
in around £2m of non-recurring costs. This impacted the pace
of product shipments in the period, which we expect to catch up in
H2.
We remain committed to our long-term
strategy of developing innovative and patented products to create
strong market positions. During the first six months of this
financial year, our gross engineering spend, including research and
development, increased by 8% to £55.5m. This increase mostly
related to labour costs, and includes £1.4m of severance costs
relating to the closure of a research site in Edinburgh,
UK.
We have controlled distribution and
administrative expenses, with no significant year-on-year increase
at actual exchange rates. This includes further increases in
third-party support and maintenance costs in relation to our
ongoing IT transformation, which will lead to productivity benefits
in future years.
Profit and
tax
Financial income less expenses for
the period was £4.1m compared with £6.8m last year. While interest
on bank deposits increased by £1.3m, we have experienced £1.7m of
currency losses (FY2024 H1: £1.0m gain) on intragroup financing
balances and mitigating forward currency swap contracts.
The resulting profit before tax for
the period was £57.5m (17% of revenue) compared with £56.5m (17% of
revenue) last financial year. In previous reporting periods, we
have reported adjusted profit measures. For this period and the
comparable period there are no adjusting items, and therefore
adjusted and statutory profit measures are equivalent.
The income tax expense in the
Consolidated income statement has been estimated at a rate of 20.1%
(H1 FY2024: 20.1%) and is based on management's best estimate of
the full year effective tax rates by geographical unit applied to
half-year profits. This compares to 21.0% in FY2024.
Earnings per share were 63.2p,
compared with 62.1p last year.
Operating profit for our
Manufacturing technologies segment, which comprises our Industrial
Metrology, Position Measurement and Additive Manufacturing
products, was £52.8m for the first six months, compared with £46.0m
for the same period in the last financial year. Our
Analytical Instruments and medical devices segment, which comprises
our Spectroscopy and Neurological products, made a loss of £1.2m in
the first six months compared with a profit of £1.2m for the same
period in the last financial year.
Cash
flow
In working capital, our trade
receivables have reduced by £21.5m, in line with the profile of our
quarterly revenue and with minimal movement in debtor days, while
we continue to carefully manage our inventory balances, which have
reduced by £4.2m to £157.8m.
We have reduced our planned capital
expenditure during the period following the significant investment
in our manufacturing facility in Wales over the previous two years.
The first of the two new halls became
operational in FY2024, which provides additional production
capacity for our physically larger products including CMMs,
additive manufacturing machines and enclosed encoders.
As a result, we have achieved strong
adjusted* cash flow conversion from operating activities of 100%,
which is above our target of 70%. Cash and cash equivalents and
bank deposit balances at 31 December 2024 were £233.2m, compared
with £217.8m at 30 June 2024, primarily reflecting cash generated
from operating activities of £76.2m, less capital expenditure of
£23.4m, and the final dividend payment of £43.2m in respect of
FY2024.
Dividend
The Board has approved an interim
dividend of 16.8p net per share (FY2024: 16.8p), which will be paid
on 8 April 2025 to shareholders on the register on 7 March
2025.
Principal
risks and uncertainties
The Board has considered the risks
and uncertainties which could have a material effect on the
Group's
performance and position. While
there is heightened uncertainty arising from geopolitical matters
and trade
tensions, these have not yet
impacted our business, and the Board continues to monitor the
situation closely. The overall impact and likelihood of our other
principal risks is not considered to have changed
significantly. This conclusion also
reflects the mitigation undertaken by the Group in response to
these
risks. The principal risks and
uncertainties set out on pages 11 to 18 of the 2024 Annual Report
therefore
remain relevant.
Sustainability
We continue to make strong progress
towards our target of Net Zero for Scopes 1
and 2 emissions by 2028. During the period, we have started work on
converting heating systems at our facility in Pliezhausen, Germany,
from oil to a lower-carbon alternative. We are also focused on
reducing our Scope 3 emissions, including working with key
suppliers to reduce the carbon impact of the materials that we use
to make our products. Last year we increased the recycled
content of our raw aluminium supply, generating annual savings of
3,000 tonnes of CO2, and are now working on further supply chain
savings with other suppliers and materials.
We continue to see significant
commercial opportunities arising from the drive towards sustainable
business practices. Our products help our customers to meet their
sustainability targets by increasing their manufacturing
efficiencies through lower energy consumption and waste, and also
by improving the performance of the products they supply to their
own customers.
Sir
David McMurtry
In December 2024, it was with
profound sadness that we announced the death of our co-founder and
Non-executive Director, Sir David McMurtry. We have since been
overwhelmed by messages of support from around the world. People
reflected on David's role as a visionary and empathetic business
leader, as a passionate innovator, how he shaped an entire
industry, and also his decency, humility and great sense of humour.
Whilst his presence is deeply missed, the ethos that he and John
Deer instilled in Renishaw continues to guide us.
Directors and
employees
The Directors would like to thank
our employees for continuing to drive us forward towards our vision
to innovate and transform the capabilities of our
customers.
Sir David McMurtry's son, Richard
McMurtry, joined the Board as a Non-executive Director in July
2024. The Renishaw Board is working to appoint an Independent
Non-executive Chair whilst continuing work on succession planning,
including additional Non-executive Director recruitment.
Outlook
The Board
remains confident in our growth model,
built on solving customer problems with innovative products, global
service and world-class in-house manufacturing. Whilst we operate
in cyclical markets, we aim for high single-digit average organic
growth rates through the cycle, to improve our operating profit
margins to above 20%, and to generate strong free cash
flow.
We have continued to make steady
progress in mixed trading conditions and our order intake has
recently improved, particularly from the semiconductor
manufacturing and consumer electronics sectors. Supported by our
strategic progress, we expect to achieve steady revenue growth this
year. Our markets present significant structural growth
opportunities, and we are confident that the investment that we are
currently making in productivity improvements will drive our
operating margins towards our 20% target in the medium
term.
At this stage we expect full year
revenue to be in the range of £695m to
£735m. Adjusted profit before tax is expected to be in the range of
£105m to £135m.
Will Lee
|
Allen Roberts
|
Chief Executive
|
Group Finance Director
|
|
|
12 February 2025
|
|
|
|
* For
this period and the comparable period there is no difference between 'Statutory' and 'Adjusted' for some of
our alternative performance measures, being Adjusted profit before
tax, Adjusted earnings per share and Adjusted operating profit.
Note 12, Alternative performance measures,
defines how other alternative measures are calculated.
Consolidated income statement
from continuing
operations
|
Notes
|
Unaudited
6 months to
31 December
2024
£'000
|
Unaudited
6 months to
31 December
2023
£'000
|
Audited
Year ended
30 June
2024
£'000
|
Revenue
|
2
|
341,402
|
330,489
|
691,301
|
|
|
|
|
|
Cost of sales
|
3
|
(182,060)
|
(175,904)
|
(367,658)
|
|
|
|
|
|
Gross profit
|
|
159,342
|
154,585
|
323,643
|
|
|
|
|
|
Distribution costs
|
|
(68,276)
|
(68,871)
|
(139,901)
|
Administrative expenses
|
|
(39,506)
|
(38,520)
|
(75,075)
|
|
|
|
|
|
Operating profit
|
|
51,560
|
47,194
|
108,667
|
|
|
|
|
|
Financial income
|
4
|
6,339
|
7,168
|
12,336
|
Financial expenses
|
4
|
(2,221)
|
(351)
|
(2,289)
|
Share of profits from joint
ventures
|
|
1,806
|
2,530
|
3,880
|
|
|
|
|
|
Profit before tax
|
|
57,484
|
56,541
|
122,594
|
|
|
|
|
|
Income tax expense
|
5
|
(11,555)
|
(11,364)
|
(25,705)
|
|
|
|
|
|
Profit for the period
|
|
45,929
|
45,177
|
96,889
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
|
Equity shareholders of the parent
company
|
|
45,929
|
45,177
|
96,889
|
Non-controlling interest
|
|
-
|
-
|
-
|
Profit for the period
|
|
45,929
|
45,177
|
96,889
|
|
|
|
|
|
|
|
Pence
|
Pence
|
Pence
|
Dividend per share arising in
respect of the period
|
7
|
16.8
|
16.8
|
76.2
|
|
|
|
|
|
Earnings per share (basic and
diluted)
|
6
|
63.2
|
62.1
|
133.2
|
​
Consolidated statement of comprehensive income and
expense
|
Unaudited
6
months to
31
December
2024
£'000
|
Unaudited
6 months to
31 December
2023
£'000
|
Audited
Year ended
30 June
2024
£'000
|
|
|
|
|
Profit for the period
|
45,929
|
45,177
|
96,889
|
|
|
|
|
Other items recognised directly in equity:
|
|
|
|
|
|
|
|
Items that will not be reclassified to the Consolidated income
statement:
|
|
|
|
Remeasurement of defined benefit
pension scheme assets/liabilities
|
732
|
(49,459)
|
(48,688)
|
Deferred tax on remeasurement of
defined benefit pension scheme assets/liabilities
|
(84)
|
12,349
|
12,424
|
|
|
|
|
Total for items that will not be
reclassified
|
648
|
(37,110)
|
(36,264)
|
|
|
|
|
Items that may be reclassified to the Consolidated income
statement:
|
|
|
|
Exchange differences in translation
of overseas operations
|
(1,864)
|
1,576
|
(4,038)
|
Exchange differences in translation
of overseas joint venture
|
(528)
|
159
|
(311)
|
Current tax on translation of net
investments in foreign operations
|
-
|
(297)
|
57
|
Effective portion of changes in fair
value of cash flow hedges, net of recycling
|
(11,188)
|
4,422
|
5,812
|
Deferred tax on effective portion of
changes in fair value of cash flow hedges
|
2,839
|
(1,105)
|
(1,453)
|
|
|
|
|
Total for items that may be reclassified
|
(10,741)
|
4,755
|
67
|
|
|
|
|
Total other comprehensive income and
expense, net of tax
|
(10,093)
|
(32,355)
|
(36,197)
|
|
|
|
|
Total comprehensive income and expense for the
period
|
35,836
|
12,822
|
60,692
|
|
|
|
|
Attributable to:
|
|
|
|
Equity shareholders of the parent
company
|
35,836
|
12,822
|
60,692
|
Non-controlling interest
|
-
|
-
|
-
|
|
|
|
|
Total comprehensive income and expense for the
period
|
35,836
|
12,822
|
60,692
|
Consolidated balance sheet
|
Notes
|
Unaudited
At 31 December
2024
£'000
|
Unaudited
At 31 December
2023*
£'000
|
Audited
At 30 June
2024
£'000
|
Assets
|
|
|
|
|
Property, plant and
equipment
|
8
|
334,997
|
318,036
|
325,040
|
Right-of-use assets
|
|
13,773
|
10,049
|
14,746
|
Investment properties
|
|
10,076
|
10,181
|
10,285
|
Intangible assets
|
9
|
49,224
|
48,319
|
47,343
|
Investments in joint
ventures
|
|
26,089
|
24,529
|
25,485
|
Finance lease receivables
|
|
14,430
|
8,814
|
11,944
|
Employee benefits
|
|
11,410
|
9,128
|
10,845
|
Deferred tax assets
|
|
17,558
|
20,006
|
17,690
|
Derivatives
|
10
|
2,052
|
3,233
|
1,387
|
Total non-current assets
|
|
479,609
|
452,295
|
464,765
|
|
|
|
|
|
Current assets
|
|
|
|
|
Inventories
|
|
157,758
|
174,383
|
161,928
|
Trade receivables
|
10
|
112,616
|
116,268
|
134,073
|
Finance lease receivables
|
|
3,382
|
3,552
|
3,861
|
Current tax
|
|
8,123
|
13,642
|
21,298
|
Other receivables
|
|
43,756
|
37,693
|
34,076
|
Derivatives
|
10
|
5,412
|
11,585
|
13,547
|
Bank deposits
|
|
143,000
|
119,000
|
95,542
|
Cash and cash equivalents
|
|
90,161
|
59,258
|
122,293
|
Total current assets
|
|
564,208
|
535,381
|
586,618
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
Trade payables
|
|
23,544
|
22,011
|
21,330
|
Contract liabilities
|
|
13,806
|
7,811
|
10,880
|
Current tax
|
|
2,662
|
1,452
|
1,767
|
Provisions
|
|
3,963
|
2,722
|
2,997
|
Derivatives
|
10
|
2,385
|
1,529
|
448
|
Lease liabilities
|
|
3,915
|
3,217
|
3,960
|
Amounts owed to joint
ventures
|
13
|
11,570
|
-
|
8,475
|
Borrowings
|
|
773
|
4,372
|
747
|
Other payables
|
|
40,059
|
43,654
|
50,344
|
Total current liabilities
|
|
102,677
|
86,768
|
100,948
|
Net current assets
|
|
461,531
|
448,613
|
485,670
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
Lease liabilities
|
|
10,313
|
7,083
|
11,062
|
Borrowings
|
|
2,491
|
-
|
2,775
|
Employee benefits
|
|
-
|
90
|
-
|
Deferred tax liabilities
|
|
30,106
|
27,007
|
33,600
|
Derivatives
|
10
|
2,520
|
-
|
177
|
Total non-current
liabilities
|
|
45,430
|
34,180
|
47,614
|
Total assets less total
liabilities
|
|
895,710
|
866,728
|
902,821
|
|
|
|
|
|
Equity
|
|
|
|
|
Share capital
|
|
14,558
|
14,558
|
14,558
|
Share premium
|
|
42
|
42
|
42
|
Own shares held
|
|
(2,367)
|
(2,963)
|
(2,963)
|
Currency translation
reserve
|
|
88
|
8,210
|
2,480
|
Cash flow hedging reserve
|
|
2,562
|
9,869
|
10,911
|
Retained earnings
|
|
880,362
|
836,649
|
876,990
|
Other reserve
|
|
1,042
|
940
|
1,380
|
Equity attributable to the
shareholders of the parent company
|
|
896,287
|
867,305
|
903,398
|
Non-controlling interest
|
|
(577)
|
(577)
|
(577)
|
Total equity
|
|
895,710
|
866,728
|
902,821
|
* December 2023 Other receivables
have been reclassified to include Contract assets.
Consolidated statement of changes in equity
Unaudited
|
Share
capital
£'000
|
Share
premium
£'000
|
Own
shares
held
£'000
|
Currency
translation
reserve
£'000
|
Cash flow
hedging
reserve
£'000
|
Retained
earnings
£'000
|
Other
reserve
£'000
|
Non-
controlling
interest
£'000
|
Total
£'000
|
Balance at 1 July 2023
|
14,558
|
42
|
(2,963)
|
6,772
|
6,552
|
871,777
|
497
|
(577)
|
896,658
|
|
|
|
|
|
|
|
|
|
|
Profit for the period
|
-
|
-
|
-
|
-
|
-
|
45,177
|
-
|
-
|
45,177
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income and
expense (net of tax)
|
|
|
|
|
|
|
|
|
|
Remeasurement of defined benefit
pension assets/liabilities
|
-
|
-
|
-
|
-
|
-
|
(37,110)
|
-
|
-
|
(37,110)
|
Foreign exchange translation
differences
|
-
|
-
|
-
|
1,279
|
-
|
-
|
-
|
-
|
1,279
|
Relating to joint
ventures
|
-
|
-
|
-
|
159
|
-
|
-
|
-
|
-
|
159
|
Changes in fair value of cash flow
hedges
|
-
|
-
|
-
|
-
|
3,317
|
-
|
-
|
-
|
3,317
|
Total other comprehensive income and
expense
|
-
|
-
|
-
|
1,438
|
3,317
|
(37,110)
|
-
|
-
|
(32,355)
|
Total comprehensive income and
expense
|
-
|
-
|
-
|
1,438
|
3,317
|
8,067
|
-
|
-
|
12,822
|
|
|
|
|
|
|
|
|
|
|
Transactions with owners recorded in
equity
|
|
|
|
|
|
|
|
|
|
Share-based payments
charge
|
-
|
-
|
-
|
-
|
-
|
-
|
443
|
-
|
443
|
Own shares purchased
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividends paid
|
-
|
-
|
-
|
-
|
-
|
(43,195)
|
-
|
-
|
(43,195)
|
Balance at 31 December
2023
|
14,558
|
42
|
(2,963)
|
8,210
|
9,869
|
836,649
|
940
|
(577)
|
866,728
|
|
|
|
|
|
|
|
|
|
|
Profit for the period
|
-
|
-
|
-
|
-
|
-
|
51,712
|
-
|
-
|
51,712
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income and
expense (net of tax)
|
|
|
|
|
|
|
|
|
|
Remeasurement of defined benefit
pension assets/liabilities
|
-
|
-
|
-
|
-
|
-
|
846
|
-
|
-
|
846
|
Foreign exchange translation
differences
|
-
|
-
|
-
|
(5,260)
|
-
|
-
|
-
|
-
|
(5,260)
|
Relating to joint
ventures
|
-
|
-
|
-
|
(470)
|
-
|
-
|
-
|
-
|
(470)
|
Changes in fair value of cash flow
hedges
|
-
|
-
|
-
|
-
|
1,042
|
-
|
-
|
-
|
1,042
|
Total other comprehensive income and
expense
|
-
|
-
|
-
|
(5,730)
|
1,042
|
846
|
-
|
-
|
(3,842)
|
Total comprehensive income and
expense
|
-
|
-
|
-
|
(5,730)
|
1,042
|
52,558
|
-
|
-
|
47,870
|
|
|
|
|
|
|
|
|
|
|
Transactions with owners recorded in
equity
|
|
|
|
|
|
|
|
|
|
Share-based payments
charge
|
-
|
-
|
-
|
-
|
-
|
-
|
440
|
-
|
440
|
Dividends paid
|
-
|
-
|
-
|
-
|
-
|
(12,217)
|
-
|
-
|
(12,217)
|
Balance at 30 June 2024
|
14,558
|
42
|
(2,963)
|
2,480
|
10,911
|
876,990
|
1,380
|
(577)
|
902,821
|
|
|
|
|
|
|
|
|
|
|
Profit for the period
|
-
|
-
|
-
|
-
|
-
|
45,929
|
-
|
-
|
45,929
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income and
expense (net of tax)
|
|
|
|
|
|
|
|
|
|
Remeasurement of defined benefit
pension assets/liabilities
|
-
|
-
|
-
|
-
|
-
|
648
|
-
|
-
|
648
|
Foreign exchange translation
differences
|
-
|
-
|
-
|
(1,864)
|
-
|
-
|
-
|
-
|
(1,864)
|
Relating to joint
ventures
|
-
|
-
|
-
|
(528)
|
-
|
-
|
-
|
-
|
(528)
|
Changes in fair value of cash flow
hedges
|
-
|
-
|
-
|
-
|
(8,349)
|
-
|
-
|
-
|
(8,349)
|
Total other comprehensive income and
expense
|
-
|
-
|
-
|
(2,392)
|
(8,349)
|
648
|
-
|
-
|
(10,093)
|
Total comprehensive income and
expense
|
-
|
-
|
-
|
(2,392)
|
(8,349)
|
46,577
|
-
|
-
|
35,836
|
|
|
|
|
|
|
|
|
|
|
Transactions with owners recorded in
equity
|
|
|
|
|
|
|
|
|
|
Share-based payments
charge
|
-
|
-
|
-
|
-
|
-
|
-
|
412
|
-
|
412
|
Distribution of own
shares
|
-
|
-
|
750
|
-
|
-
|
-
|
(750)
|
-
|
-
|
Purchase of own shares
|
-
|
-
|
(154)
|
-
|
-
|
-
|
-
|
-
|
(154)
|
Dividends paid
|
-
|
-
|
-
|
-
|
-
|
(43,205)
|
-
|
-
|
(43,205)
|
Balance at 31 December
2024
|
14,558
|
42
|
(2,367)
|
88
|
2,562
|
880,362
|
1,042
|
(577)
|
895,710
|
Consolidated statement of cash flow
|
Unaudited
6 months to
31 December
2024
£'000
|
Unaudited
6 months to
31 December
2023
£'000
|
Audited
Year ended
30 June
2024
£'000
|
Cash flows from operating
activities
|
|
|
|
Profit for the period
|
45,929
|
45,177
|
96,889
|
Adjustments for:
|
|
|
|
Depreciation of property, plant and
equipment, right-of-use assets, and investment
properties
|
12,278
|
11,506
|
24,195
|
Profit on sale of property, plant
and equipment
|
(1,005)
|
(29)
|
(1,199)
|
Amortisation and impairment of
intangible assets
|
2,394
|
2,888
|
8,633
|
Share of profits from joint
ventures
|
(1,806)
|
(2,530)
|
(3,880)
|
Defined benefit pension scheme past
service and administrative costs
|
494
|
397
|
907
|
Financial income
|
(6,339)
|
(7,168)
|
(12,336)
|
Financial expenses
|
2,221
|
351
|
2,289
|
Share based payment
expense
|
412
|
445
|
883
|
Tax expense
|
11,555
|
11,364
|
25,705
|
|
20,204
|
17,224
|
45,197
|
Decrease in inventories
|
4,170
|
11,374
|
23,829
|
Decrease/(increase) in trade and
other receivables
|
8,337
|
486
|
(23,719)
|
Increase/(decrease) in trade and
other payables
|
(5,101)
|
(6,381)
|
3,557
|
Increase/(decrease) in
provisions
|
966
|
(36)
|
239
|
|
8,372
|
5,443
|
3,906
|
Defined benefit pension scheme
contributions
|
(79)
|
(83)
|
(161)
|
Income taxes
received/(paid)
|
1,815
|
(12,191)
|
(21,752)
|
Cash flows from operating
activities
|
76,241
|
55,350
|
124,079
|
|
|
|
|
Investing activities
|
|
|
|
Purchase of property, plant and
equipment, and investment properties
|
(23,352)
|
(40,443)
|
(65,518)
|
Sale of property, plant and
equipment
|
2,814
|
200
|
4,475
|
Development costs
capitalised
|
(4,079)
|
(4,542)
|
(9,281)
|
Purchase of other
intangibles
|
(226)
|
(30)
|
(246)
|
(Increase)/decrease in bank
deposits
|
(47,458)
|
6,000
|
29,458
|
Interest received
|
6,091
|
4,745
|
9,110
|
Dividend received from joint
venture
|
674
|
573
|
498
|
Cash flows from investing
activities
|
(65,536)
|
(33,497)
|
(31,504)
|
|
|
|
|
Financing activities
|
|
|
|
Repayment of borrowings
|
(390)
|
(393)
|
(799)
|
Amounts received as deposit from
joint venture
|
3,361
|
-
|
8,475
|
Interest paid
|
(491)
|
(351)
|
(608)
|
Repayment of principal of lease
liabilities
|
(2,069)
|
(2,607)
|
(4,359)
|
Own shares purchased
|
(154)
|
-
|
-
|
Dividends paid
|
(43,205)
|
(43,195)
|
(55,412)
|
Cash flows from financing
activities
|
(42,948)
|
(46,546)
|
(52,703)
|
|
|
|
|
Net (decrease)/increase in cash and
cash equivalents
|
(32,243)
|
(24,473)
|
39,872
|
Cash and cash equivalents at the
beginning of the period
|
122,293
|
81,388
|
81,388
|
Effect of exchange rate fluctuations
on cash held
|
111
|
2,343
|
1,033
|
Cash and cash equivalents at the end
of the period
|
90,161
|
59,258
|
122,293
|
Cash and cash equivalents and bank
deposits at 31 December 2024 were £233.2m (30 June 2024:
£217.8m).
Notes
1.
Basis of preparation
The Interim report, which includes the
condensed consolidated financial statements for the six months
ended 31 December 2024, was approved by the Directors on 12
February 2025.
The condensed consolidated financial
statements for the six months ended 31 December 2024 were prepared
in accordance with International Accounting Standard 34 'Interim
Financial Reporting' (IAS 34) as issued by the International
Accounting Standards Board and as adopted by the UK. These apply
the same accounting policies, presentation and methods of
calculation as were applied in the preparation of the Group's
consolidated financial statements for the year ended 30 June 2024,
except for income taxes which are accrued using the forecast tax
rate for the financial year.
The condensed consolidated financial
statements included in this Report have not been audited and do not
constitute the Group's statutory accounts as defined in section 434
of the Companies Act 2006. The information relating to the year
ended 30 June 2024 is an extract from the Group's published Annual
Report for that year, which has been delivered to the Registrar of
Companies, and on which the auditor's report was unqualified and
did not contain any emphasis of matter or statements under section
498(2) or 498(3) of the Companies Act 2006.
Going
concern
The Directors have prepared the unaudited
interim financial information on a going concern basis. In
considering the going concern basis, the Directors have considered
the previously mentioned principal risks and uncertainties, as well
as the Group's current trading performance and updated cashflow
forecasts. The Directors have also considered the financial
resources available to the Group, with net current assets of
£461.5m at 31 December 2024 (compared to £485.7m at 30 June 2024),
including £233.2m cash and cash equivalents and bank deposits at 31
December 2024.
We have updated our reverse stress testing to
identify what would need to happen in the period to 28 February
2026 for the Group to deplete its cash and cash equivalents and
bank deposit balances. This identified a trading level so low
(significantly below FY2024 revenue) that the Directors feel that
the events that could trigger this would be remote. The Directors
also concluded that a one-off cash outflow that would exhaust the
Group's cash and cash equivalents and bank deposit balances in the
assessment period was also remote.
Based on this assessment, the Directors have a
reasonable expectation that the Group will be able to continue in
operation and meet its liabilities as they fall due over the period
to 28 February 2026.
2.
Revenue disaggregation and segmental
analysis
Within the Manufacturing technologies segment
there are multiple product offerings with similar economic
characteristics, similar production processes and similar customer
bases. Our Manufacturing technologies segment consists of
Industrial Metrology, Position Measurement and Additive
Manufacturing product groups. Analytical instruments and medical
devices segment comprises our Spectroscopy and Neurological product
lines. More details of the Group's products and services are given
in the Strategic Report of the 2024 Annual Report.
In normal trading conditions, whilst future
revenue is difficult to predict given that the Group's outstanding
order book is typically less than three months' worth of revenue
value, larger consumer electronics orders in the APAC region within
the Manufacturing technologies segment typically fall in the first
or last quarter of the financial year. In addition, the Group
typically experiences lower demand in August and December, and so
revenue and operating profits are typically lower in the first half
of the year. This information is provided to allow for a better
understanding of the results, and management do not believe that
the business is 'highly seasonal' in accordance with IAS
34.
|
Manufacturing
technologies
|
Analytical instruments and medical
devices
|
Total
|
6
months to 31 December 2024
|
£'000
|
£'000
|
£'000
|
Revenue
|
322,625
|
18,777
|
341,402
|
Depreciation, amortisation and
impairment
|
13,780
|
892
|
14,672
|
Operating profit
|
52,774
|
(1,214)
|
51,560
|
Share of profits from joint
ventures
|
1,806
|
-
|
1,806
|
Net financial income
|
-
|
-
|
4,118
|
Profit before tax
|
-
|
-
|
57,484
|
2.
Segmental information
(continued)
|
Manufacturing
technologies
|
Analytical instruments and
medical devices
|
Total
|
6
months to 31 December 2023
|
£'000
|
£'000
|
£'000
|
Revenue
|
311,069
|
19,420
|
330,489
|
Depreciation, amortisation and
impairment
|
13,391
|
783
|
14,174
|
Operating profit
|
45,953
|
1,241
|
47,194
|
Share of profits from joint
ventures
|
2,530
|
-
|
2,530
|
Net financial
income/(expense)
|
-
|
-
|
6,817
|
Profit before tax
|
-
|
-
|
56,541
|
|
|
|
|
Year
ended 30 June 2024
|
|
|
|
Revenue
|
648,063
|
43,238
|
691,301
|
Depreciation, amortisation and
impairment
|
31,374
|
1,454
|
32,828
|
Operating profit
|
103,181
|
5,486
|
108,667
|
Share of profits from joint
ventures
|
3,880
|
-
|
3,880
|
Net financial
income/(expense)
|
-
|
-
|
10,047
|
Profit before tax
|
-
|
-
|
122,594
|
There is no allocation of assets and
liabilities to segments identified above. Depreciation,
amortisation and impairments are allocated to segments on the basis
of the level of activity.
The following table shows the disaggregation
of Group revenue by category:
|
6 months to
31 December
2024
£'000
|
6 months
to
31
December
2023
£'000
|
Year
ended
30 June
2024
£'000
|
Goods, capital equipment and
installation
|
306,441
|
300,745
|
624,491
|
Aftermarket services
|
34,961
|
29,744
|
66,810
|
Total Group revenue
|
341,402
|
330,489
|
691,301
|
Aftermarket services include repairs,
maintenance and servicing, programming, training, extended
warranties, and software licences and maintenance. There is no
significant difference between our two reporting segments as to
their split of revenue by type.
The following table shows the analysis of
revenue by geographical market:
|
6 months to
31 December
2024
£'000
|
6 months
to
31
December
2023
£'000
|
Year
ended
30 June
2024
£'000
|
APAC
|
161,366
|
161,199
|
318,836
|
UK (country of domicile)
|
18,825
|
17,173
|
37,956
|
EMEA, excluding UK
|
83,486
|
80,035
|
170,077
|
EMEA
|
102,311
|
97,208
|
208,033
|
Americas
|
77,725
|
72,082
|
164,432
|
Total Group revenue
|
341,402
|
330,489
|
691,301
|
Revenue in the previous table has been
allocated to regions based on the geographical location of the
customer. Countries with individually significant revenue figures
in the context of the Group were:
|
6 months to
31 December
2024
£'000
|
6 months
to
31
December
2023
£'000
|
Year
ended
30 June
2024
£'000
|
China
|
87,976
|
90,369
|
177,155
|
USA
|
67,345
|
60,707
|
138,836
|
Japan
|
25,036
|
26,366
|
54,572
|
Germany
|
28,175
|
25,646
|
49,329
|
There was no revenue from transactions with a
single external customer amounting to 10% or more of the Group's
total revenue.
3.
Cost of sales
|
6 months to
31 December
2024
£'000
|
6 months
to
31
December
2023
£'000
|
Year
ended
30 June
2024
£'000
|
|
|
|
|
Production costs
|
131,486
|
130,473
|
269,562
|
Research and development expenditure
|
33,781
|
32,156
|
71,060
|
Other engineering expenditure
|
21,758
|
19,390
|
35,723
|
Gross engineering expenditure
|
55,539
|
51,546
|
106,783
|
Development expenditure capitalised (net of
amortisation)
|
(1,855)
|
(2,065)
|
(4,287)
|
Development expenditure impaired
|
-
|
-
|
3,299
|
Research and development tax credit
|
(3,110)
|
(4,050)
|
(7,699)
|
Total engineering costs
|
50,574
|
45,431
|
98,096
|
Total cost of sales
|
182,060
|
175,904
|
367,658
|
4.
Financial income and
expenses
|
6 months to
31 December
2024
£'000
|
6 months
to
31
December
2023
£'000
|
Year
ended
30 June
2024
£'000
|
Financial
income
|
|
|
|
Bank interest receivable
|
6,091
|
4,745
|
9,110
|
Interest on pension schemes' assets
|
248
|
1,439
|
2,908
|
Fair value gains from one-month forward currency
contracts
|
-
|
380
|
318
|
Currency gains
|
-
|
604
|
-
|
Total financial income
|
6,339
|
7,168
|
12,336
|
Financial
expenses
|
|
|
|
Currency losses
|
1,448
|
-
|
1,645
|
Lease interest
|
348
|
214
|
537
|
Fair value losses from one-month forward
currency contracts
|
264
|
-
|
-
|
Interest payable on amounts owed to joint
ventures
|
74
|
-
|
55
|
Interest payable on borrowings
|
18
|
24
|
36
|
Other interest payable
|
69
|
113
|
16
|
Total financial expenses
|
2,221
|
351
|
2,289
|
Currency losses relate to
revaluations of foreign currency-denominated balances using latest
reporting currency exchange rates. The losses recognised in FY2025
H1 largely related to an appreciation of Sterling relative to the
Mexican Peso affecting intragroup balances in the Company. We
converted this intra group balance to share capital towards the end
of H1 such that we are no longer exposed to the related currency
risk.
Rolling one-month forward currency
contracts are used to offset currency movements on certain
intragroup balances, with fair value gains and losses being
recognised in financial income or expenses.
5.
Taxation
The income tax expense in the Consolidated
income statement has been estimated at a rate of 20.1% (H1 FY2024:
20.1%), based on management's best estimate of the full year
effective tax rates by geographical unit, applied to half-year
profits. This compares to 21.0% in
FY2024.
6.
Earnings per share
The earnings per share for the six months ended
31 December 2024 is calculated on earnings of £45,929,000 (31
December 2023: £45,177,000) and on 72,729,059 shares (31 December
2023: 72,719,565 shares), being the number of shares in issue
during the period. This excludes 59,484 shares (31 December 2023:
68,978 shares) held by the Renishaw Employee Benefit
Trust.
7.
Dividends
Dividends paid during the period
were:
|
6 months to
31 December
2024
£'000
|
6 months
to
31
December
2023
£'000
|
Year
ended
30 June
2024
£'000
|
|
|
|
|
FY2024 final dividend paid of 59.4p per share
(FY2023: 59.4p)
|
43,205
|
43,195
|
43,195
|
FY2024 Interim dividend paid of 16.8p per share
(FY2023: 16.8p)
|
-
|
-
|
12,217
|
Total dividends paid during the
period
|
43,205
|
43,195
|
55,412
|
All shareholders on the register on 7 March
2025 will be paid an interim dividend of 16.8p net per share on 8
April 2025, resulting in a dividend payable of
£12,218,000.
8.
Property, plant and
equipment
|
Freehold
land and
buildings
|
Plant and
equipment
|
Motor
vehicles
|
Assets in the
course of construction
|
Total
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
Cost
|
|
|
|
|
|
At 1 July 2024
|
255,536
|
278,189
|
6,099
|
56,593
|
596,417
|
Additions
|
81
|
11,174
|
712
|
11,385
|
23,352
|
Transfers
|
2,284
|
6,430
|
-
|
(8,714)
|
-
|
Disposals
|
(527)
|
(2,936)
|
(564)
|
-
|
(4,027)
|
Currency adjustment
|
(1,550)
|
(1,248)
|
(83)
|
-
|
(2,881)
|
|
|
|
|
|
|
At 31 December
2024
|
255,824
|
291,609
|
6,164
|
59,264
|
612,861
|
|
|
|
|
|
|
Depreciation
|
|
|
|
|
|
At 1 July 2024
|
49,460
|
216,838
|
5,079
|
-
|
271,377
|
Charge for the period
|
2,548
|
7,221
|
153
|
-
|
9,922
|
Disposals
|
(251)
|
(1,551)
|
(416)
|
-
|
(2,218)
|
Currency adjustment
|
(361)
|
(792)
|
(64)
|
-
|
(1,217)
|
|
|
|
|
|
|
At 31 December
2024
|
51,396
|
221,716
|
4,752
|
-
|
277,864
|
|
|
|
|
|
|
Net book
value
|
|
|
|
|
|
At 31 December
2024
|
204,428
|
69,893
|
1,412
|
59,264
|
334,997
|
At 30 June 2024
|
206,076
|
61,351
|
1,020
|
56,593
|
325,040
|
Additions to assets in the course of
construction of £11,385,000 (31 December 2023: £35,939,000)
comprise £3,752,000 (31 December 2023: £25,685,000) for freehold
land and buildings and £7,633,000 (31 December 2023: £10,254,000)
for plant and equipment. At the end of the period, assets in the
course of construction, not yet transferred, of £59,264,000 (31
December 2023: £83,553,000) comprise £35,969,000 (31 December 2023:
£62,777,000) for freehold land and buildings and £23,295,000 (31
December 2023: £20,776,000) for plant and equipment. This mostly
relates to the expansion of our manufacturing facility in Miskin,
Wales.
9.
Intangible assets
|
Goodwill
|
Internally
generated
development costs
|
Software licences
|
Intellectual property and other
intangible assets
|
Total
|
|
£'000
|
£'000
|
£'000
|
£'000
|
£'000
|
Cost
|
|
|
|
|
|
At 1 July 2024
|
20,258
|
187,941
|
12,197
|
4,864
|
220,301
|
Additions
|
-
|
4,079
|
226
|
-
|
4,305
|
Currency adjustment
|
(5)
|
-
|
(39)
|
(10)
|
(54)
|
|
|
|
|
|
|
At 31 December
2024
|
20,253
|
192,020
|
12,384
|
4,854
|
229,511
|
|
|
|
|
|
|
Amortisation
|
|
|
|
|
|
At 1 July 2024
|
9,028
|
154,531
|
11,751
|
2,607
|
177,917
|
Charge for the period
|
-
|
2,224
|
86
|
84
|
2,394
|
Currency adjustment
|
-
|
-
|
(34)
|
10
|
(24)
|
|
|
|
|
|
|
At 31 December
2024
|
9,028
|
156,755
|
11,803
|
2,701
|
180,287
|
|
|
|
|
|
|
Net book
value
|
|
|
|
|
|
At 31 December
2024
|
11,225
|
35,265
|
581
|
2,153
|
49,224
|
At 30 June 2024
|
11,230
|
33,410
|
446
|
2,257
|
47,343
|
As detailed in the 2024 Annual Report, the key
assumption in determining the value-in-use of intangible assets are
sales forecasts. Latest sales forecasts, and other factors which
may impact the business plans, for relevant cash generating units
have been reviewed for indicators of impairment on 31 December
2024. This includes an assessment of our discount rate based on
prevailing market assumptions on 31 December 2024, which has
increased to 10.9% based on a higher risk-free rate (31 December
2023: 10.7%). As a result of the review, no impairments have been
recognised in the six months to 31 December 2024 (31 December 2023:
nil).
10. Financial
instruments
There is no significant difference between the
fair value of financial assets and financial liabilities and their
book value in the Consolidated balance sheet. All financial assets
and liabilities are held at amortised cost, apart from the forward
exchange contracts which are held at fair value, with changes going
through the Consolidated income statement unless subject to hedge
accounting. The fair values of the forward exchange contracts have
been calculated by a third-party expert, discounting estimated
future cash flows on the basis of market expectations of future
exchange rates, representing level 2 in the IFRS 13 fair value
hierarchy. There were no transfers between levels during any period
disclosed.
Credit
risk
The Group carries a credit risk relating to
non-payment of trade receivables by its customers. The Group
establishes an allowance for impairment in respect of trade
receivables where recoverability is considered doubtful. In the six
months to 31 December 2024, the Group has generally not experienced
a deterioration in debtor repayments nor in the assumptions used in
calculating allowances for expected credit losses. At 31 December
2024, total expected credit losses amounted to £4,756,000, being
4.1% of gross trade receivables, compared with £4,480,000 at 30
June 2024, being 3.2% of gross trade receivables.
Liquidity
risk
The Group's approach to managing liquidity is
to ensure, as far as possible, that we will always have sufficient
liquidity to meet our liabilities when due, without incurring
unacceptable losses or risking damage to the Group's reputation. We
use monthly cash flow forecasts on a rolling 12-month basis to
monitor cash requirements. Net cash and bank deposits on 31
December 2024 totalled £233,161,000, compared with £217,835,000 at
30 June 2024. This increase included a dividend payment of
£43,205,000 and cash generation from operating activities of
£76,241,000 during the period. In
consideration of this, the Group remains in a strong liquidity
position.
10. Financial instruments
(continued)
Market
risk
The Group continues to mitigate market risk on
cash flows using USD, EUR and JPY forward currency contracts. At 31
December 2024 the total nominal value of USD, EUR and JPY forward
contracts held for cash flow hedging purposes was £450,775,855 (31
December 2023: £414,873,000). At 31 December 2024, there were no
remaining USD, EUR or JPY forward contracts ineffective for cash
flow hedging and yet to mature (31 December 2023: nil), with no
additional forward contracts becoming ineffective for hedge
accounting purposes in the six months to 31 December 2024. A
decrease of 10% in the highly probable revenue forecasts of
Renishaw plc and Renishaw UK Sales Limited, being the hedged item,
would result in no forward contracts becoming ineffective on 31
December 2024.
11. Employee
benefits
The net surplus of the Group's defined benefit
pension schemes, on an IAS 19 basis, has increased from a
£10,845,000 asset at 30 June 2024 to a £11,410,000 asset at 31
December 2024. This mostly relates to a reduction in liabilities
within the Irish scheme due to strong asset growth. During FY2024,
the Trustee of the UK scheme undertook a buy-in and insured around
99% of the UK scheme's liabilities by purchasing an insurance
policy. This contract was effective from 19 October 2023 and the
value of the contract is recognised as a UK scheme asset. The
buy-in eliminates investment return, longevity, inflation and
funding risks in respect of those liabilities covered. Changes to
other key assumptions from 30 June 2024 to 31 December 2024 have
not had a material effect on the schemes.
Benefits in the UK Scheme are subject to a DC
underpin at the point of retirement or transfer out. Historically,
this has been allowed for in the accounts in a consistent manner to
current administrative practice and the triennial funding
valuations. During the buy-in process, it was identified that the
drafting of the DC underpin in the UK Scheme Rules may require that
the DC underpin is applied in a manner which is different to the
administrative practice which has been applied. The Trustee and
Company are currently seeking legal clarification and advice on
this issue, with the intention of correcting the Rules to match
administrative practice. No allowance for this matter has been made
in 31 December 2024, as management continue to assess it to be
unlikely that there will be an increase in liabilities, and due to
the uncertainty of legal treatment and therefore any potential
impact on liabilities.
In June 2023, the High Court ruled that certain
historic amendments made to the rules of the Virgin Media pension
scheme were invalid without the scheme's actuary having provided
the associated Section 37 certificates. This judgment was upheld by
the Court of Appeal in July 2024, which has implications on other
schemes that were contracted-out on a salary-related basis, and
made amendments between April 1997 and April 2016. The UK scheme
was contracted out until 5 April 2007 and amendments were made
during the relevant period and as such the ruling could have
implications for the UK scheme. Since June 2024, the Company and
the Trustees have commenced a review of all amending documents
between 6 April 1997 and 5 April 2016 for the scheme to determine
whether proper procedures were undertaken at the time of the
amendments by the Trustees, actuaries and administrators. At the
date of approving these interim financial statements, the possible
implications, if any, for the UK scheme not having all Section 37
certificates have not been investigated in detail. The Trustee and
Company continue to seek legal advice on this matter and will act
appropriately. Accordingly, no amendments for this matter have been
included in the IAS 19 actuarial valuation as the impact, if any,
cannot be reliably assessed.
12. Alternative performance
measures
In accordance with Renishaw's Alternative
Performance Measures (APMs) policy and ESMA Guidelines on
Alternative Performance Measures (2015), this section defines
non-IFRS measures that we believe give readers additional useful
and comparable views of our underlying performance. We continue to
report Revenue at constant exchange rates, Adjusted profit before
tax, Adjusted earnings per share, Adjusted operating profit,
Adjusted operating profit at constant exchange rates, Adjusted cash
flow conversion from operating activities, and Return on invested
capital.
Revenue at constant exchange rates is defined
as revenue recalculated using the same rates as were applicable to
the previous year and excluding forward contract gains and
losses.
12. Alternative performance measures
(continued)
Revenue at constant exchange rates
|
|
6 months to 31 December
2024
|
6 months to 31
December 2023
|
|
|
£'000
|
£'000
|
|
|
|
|
Statutory revenue as reported
|
|
341,402
|
330,489
|
Adjustment for forward contract
(gains)/losses
|
|
(12,959)
|
1,853
|
Adjustment to restate at previous year
exchange rates
|
|
11,342
|
-
|
Revenue at constant exchange rates
|
|
339,785
|
332,342
|
Year-on-year revenue growth at constant
exchange rates
|
|
2%
|
-
|
For this period and the comparable
period there is no difference between 'Statutory' and
'Adjusted' for our alternative performance measures, being Adjusted
profit before tax, Adjusted earnings per share and Adjusted
operating profit, including segmental operating profit.
Operating profit at constant
exchange rates is defined as Operating profit recalculated using
the same rates as applied to the previous year and excluding
forward contract gains and losses.
Operating profit at constant exchange
rates
|
|
6 months to 31 December
2024
|
6 months to 31
December 2023
|
|
|
£'000
|
£'000
|
|
|
|
|
Operating profit
|
|
51,560
|
47,194
|
Adjustment for forward contract
(gains)/losses
|
|
(12,959)
|
1,853
|
Adjustment to restate current year at previous
year exchange rates
|
|
8,042
|
-
|
Operating profit at constant exchange
rates
|
|
46,643
|
49,047
|
Year-on-year Operating profit reduction at
constant exchange rates
|
|
-4.9%
|
|
Adjusted cash flow conversion from
operating activities is calculated as Adjusted cash flow from
operating activities as a proportion of Adjusted operating profit.
This is useful for the Board to measure how efficient we are at
converting operating profit into cash.
Adjusted cash flow conversion from operating
activities
|
6 months to 31 December
2024
|
6 months to 31
December 2023
|
Year ended 30 June
2024
|
|
£'000
|
£'000
|
£'000
|
Cash flow from operating
activities
|
76,241
|
55,570
|
124,079
|
Income taxes paid
|
(1,815)
|
12,191
|
21,752
|
Purchase of property, plant and equipment and
intangible assets
|
(25,746)
|
(45,015)
|
(74,774)
|
Proceeds from sale of property, plant and
equipment and intangible assets
|
2,814
|
200
|
4,475
|
Adjusted cash flow from operating
activities
|
51,494
|
22,946
|
75,532
|
Adjusted cash flow conversion from operating
activities
|
99.9%
|
48.6%
|
69.5%
|
Return on invested capital is the
profit after tax before bank interest receivable as a percentage of
the Average invested capital in the year. This is useful for the
Board to measure our efficiency in allocating capital to profitable
activities.
Profit after tax before bank
interest receivable is calculated as follows:
|
6 months to 31 December
2024
|
6 months to 31
December 2023
|
Year ended 30 June
2024
|
|
£'000
|
£'000
|
£'000
|
Profit after tax
|
45,929
|
45,177
|
96,889
|
Bank interest receivable (net of
tax)
|
(4,568)
|
(3,559)
|
(6,832)
|
Profit after tax before bank interest
received
|
41,361
|
41,618
|
90,057
|
Profit after tax before bank
interest received for the 12-months to 31 December 2024 was
£89.8m.
12. Alternative performance
measures (continued)
Return on invested capital (ROIC):
|
6 months to 31 December
2024
|
6 months to 31
December 2023
|
Year ended 30 June
2024
|
Year ended 30 June
2023
|
|
£'000
|
£'000
|
£'000
|
£'000
|
Total non-current assets
|
479,609
|
452,295
|
464,765
|
470,430
|
Total current assets
|
564,208
|
535,381
|
586,618
|
573,107
|
Total current liabilities
|
(102,677)
|
(86,768)
|
(100,948)
|
(102,320)
|
Less cash and cash equivalent
|
(90,161)
|
(59,258)
|
(122,293)
|
(81,388)
|
Less bank deposits
|
(143,000)
|
(119,000)
|
(95,542)
|
(125,000)
|
Invested capital
|
707,979
|
722,650
|
732,600
|
734,829
|
Average invested capital
|
715,314
|
-
|
733,715
|
-
|
Return on invested capital
|
12.6%
|
-
|
12.3%
|
-
|
Average invested capital in the
year is the average of the invested capital at the beginning of the
reporting period and at the end of the reporting period.
13. Related party transactions and
events subsequent to the end of the reporting
period
Transactions between the Company and its
subsidiaries, which are related parties, have been eliminated on
consolidation and are not disclosed in this note. Full details of
the Group's other related party relationships, transactions and
balances are given in the Group's Annual Report for the year ended
30 June 2024.
During FY2024, Renishaw International Limited
('RIL') entered into a 14-day notice deposit agreement with RLS
Merilna tehnika d.o.o. ('RLS'). Interest is payable by RIL to RLS
at a market rate on a monthly basis. As at 31 December 2024,
according to this agreement, the amount RIL had received was EUR
14.0m (£11.6m equivalent), an increase from EUR 10.0m (£8.5m
equivalent) at 30 June 2024. The amounts are recognised as 'amounts
payable to joint venture' in the Consolidated balance
sheet.
No other related party transactions have taken
place in the first six months of FY2025, or events subsequent to
the end of the reporting period, that have materially affected the
financial position or the performance of the Group during that
period.
14.
Responsibility
statement
The condensed set of financial statements is
the responsibility of, and has been approved by, the Directors. We
confirm that to the best of our knowledge:
- As required
by DTR 4.2 of the Disclosure Rules and Transparency Rules, the
condensed set of financial statements, which has been prepared in
accordance with the applicable set of accounting standards, gives a
true and fair view of the assets, liabilities, financial position
and profit or loss of the Company and the undertakings included in
the consolidation as a whole. The Interim report has been prepared
in accordance with IAS 34, 'Interim Financial Reporting', as issued
by the International Accounting Standards Board and as adopted by
the UK.
- The Interim
report includes a fair review of the information required
by:
(a) DTR 4.2.7 of the Disclosure Rules and
Transparency Rules, being an indication of important events that
have occurred during the first six months of the financial year and
their impact on the condensed set of financial statements; and a
description of the principal risks and uncertainties for the
remaining six months of the year; and
(b) DTR 4.2.8 of the Disclosure Rules and
Transparency Rules, being related party transactions that have
taken place in the first six months of the current financial year
and that have materially affected the financial position or
performance of the entity during that period; and any changes in
the related party transactions described in the last Annual Report
that could do so.
On behalf of the Board
Allen Roberts FCA
Group Finance Director
12 February 2025
Registered
office:
Renishaw plc, New Mills, Wotton-under-Edge,
Gloucestershire GL12 8JR, U.K.
Registered number:
|
01106260
|
Company Secretary:
|
companysecretary@renishaw.com
|
Telephone:
|
+44 1453 524524
|
Website:
|
www.renishaw.com
|